Skip to main navigation Skip to search Skip to main content

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

  • Bruno Dubois*
  • , Harald Hampel
  • , Howard H. Feldman
  • , Philip Scheltens
  • , Paul Aisen
  • , Sandrine Andrieu
  • , Hovagim Bakardjian
  • , Habib Benali
  • , Lars Bertram
  • , Kaj Blennow
  • , Karl Broich
  • , Enrica Cavedo
  • , Sebastian Crutch
  • , Jean François Dartigues
  • , Charles Duyckaerts
  • , Stéphane Epelbaum
  • , Giovanni B. Frisoni
  • , Serge Gauthier
  • , Remy Genthon
  • , Alida A. Gouw
  • Marie Odile Habert, David M. Holtzman, Miia Kivipelto, Simone Lista, José Luis Molinuevo, Sid E. O'Bryant, Gil D. Rabinovici, Christopher Rowe, Stephen Salloway, Lon S. Schneider, Reisa Sperling, Marc Teichmann, Maria C. Carrillo, Jeffrey Cummings, Cliff R. Jack
*Corresponding author for this work
  • Hôpital de la Pitié-Salpêtrière
  • University of British Columbia
  • University of Amsterdam
  • University of Southern California
  • Institut des Neurosciences Translationnelles de Paris
  • University of Gothenburg
  • Federal Institute for Drugs and Medical Devices
  • IRCCS Centro San Giovanni di Dio Fatebenefratelli - Brescia
  • Dementia Research Centre
  • University of Bordeaux
  • Pierre and Marie Curie University (UPMC, Paris 6)and Medical School
  • University Hospital and Medical Faculty
  • Douglas Mental Health Research Institute
  • Washington University in St. Louis
  • Karolinska Institutet
  • University Hospital of Kuopio
  • Barcelonaßeta Brain Research Center
  • Pasqual Maragall Foundation
  • University of North Texas
  • Parkinson's Disease Research Education and Clinical Center
  • University of California San Francisco
  • University of Melbourne
  • Brown University
  • Keck School of Medicine of USC
  • Harvard University
  • National Alzheimer's Association
  • Cleveland Clinic Lou Ruvo Center for Brain Health
  • Mayo Clinic Rochester, MN
  • AXA

Abstract

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

Original languageEnglish
JournalAlzheimer's and Dementia
Volume12
Issue number3
Pages (from-to)292-323
Number of pages32
ISSN1552-5260
DOIs
Publication statusPublished - 01.03.2016

Funding

H.H. is supported by the AXA Research Fund , the Fondation Université Pierre et Marie Curie , and the “Fondation pour la Recherche sur Alzheimer” , Paris, France. The research leading to these results has received funding from the program “ Investissements d'avenir ” ANR-10-IAIHU-06. S.L. is supported by the European Medical Information Framework (EMIF). R.S. is supported by the National Institute on Aging and Alzheimer's Association . The authors acknowledge the helpful contribution of Zaven Khachaturian as an advisor to the Working Group in charge of the article. The meeting was supported by the French International Foundation for Research in Alzheimer's disease (IFRAD).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria'. Together they form a unique fingerprint.

Cite this